Can Creative Proteomics support unlisted immunosuppressive compounds?

Yes. Custom workflows for CYP3A4 strong inhibitors, CYP3A4 pure substrates, UGT Phase II substrates, and mixed-mechanism immunosuppressant panels.

How do cyclosporine A and tacrolimus differ from sirolimus and everolimus in DDI risk?

Cyclosporine A and tacrolimus are CYP3A4 strong inhibitors — they suppress CYP3A4 probe substrate metabolism to near-zero, producing false-positive DDI signals in co-incubated assays. Sirolimus and everolimus are CYP3A4 substrates only (substrate, no inhibitor) — their DDI risk is being inhibited by other drugs, not inhibiting others. Standard CYP3A4 incubation without inhibitor-compensated controls cannot distinguish these groups.

Can immunosuppressive drugs be combined in custom panels?

Yes. Mechanism-matched panels use inhibitor-compensated CYP3A4 arms for cyclosporine A and tacrolimus, standard CYP3A4 arms for sirolimus and everolimus, and UDPGA arms for mycophenolic acid — three arms in one study.

Immunosuppressants Library

Immunosuppressive Drugs DMPK and Bioanalytical Services

Immunosuppressant bioanalysis is a three-way divide no preceding page combined into one class: cyclosporine A and tacrolimus are CYP3A4 strong inhibitors requiring inhibitor-compensated DDI controls; sirolimus and everolimus are pure CYP3A4 substrates needing standard NADPH incubation; mycophenolic acid is UGT Phase II, UDPGA-only, responding to none of the CYP3A4 conditions that serve the other four. A single CYP3A4 incubation produces false-positive DDI data for CsA and tacrolimus, usable data for sirolimus and everolimus, and zero glucuronidation data for mycophenolic acid.

Creative Proteomics provides CYP3A4 strong-inhibitor DDI, pure-substrate metabolism, UGT glucuronidation, and custom multi-mechanism immunosuppressant panels.

Browse Drug Index Request Custom Method Support

CYP3A4 Strong Inhibitors: CsA & TacrolimusCyclosporine A and tacrolimus suppress CYP3A4 probe activity to near-zero. Standard incubation produces false-positive DDI signals.

Pure CYP3A4 Substrates: Sirolimus & EverolimusSubstrate only, no inhibitor status. Require standard CYP3A4 incubation without inhibitor compensation.

Mycophenolic Acid: UGT Phase II OutlierUGT1A9/2B7 glucuronidation, UDPGA cofactor. Responds to none of the CYP3A4 conditions serving the other four.

Immunosuppressant Mechanism Divide DMPK Strategy Map

⚡

Three-Way ClassificationCYP3A4 strong inhibitor (CsA, tacrolimus), CYP3A4 pure substrate (sirolimus, everolimus), UGT Phase II (mycophenolic acid) — three analytical protocols, five compounds.

🧬

CYP3A4 Strong-Inhibitor DDICyclosporine A and tacrolimus require inhibitor-compensated sequential incubation — probe substrate activity measured before and after inhibitor separation.

📊

CYP3A4 Pure SubstrateSirolimus and everolimus — standard NADPH-supplemented microsome incubation. No inhibitor compensation needed.

🔬

UGT Phase II GlucuronidationMycophenolic acid: UGT1A9/2B7 with UDPGA cofactor. No CYP involvement — not CYP3A4, not P-gp.

Immunosuppressant mechanism triage before method development.Creative Proteomics classifies each compound as CYP3A4 strong inhibitor, CYP3A4 pure substrate, or UGT Phase II substrate — because CsA and sirolimus share the same CYP3A4 enzyme but require incompatible DDI protocols, and mycophenolic acid needs a completely different cofactor system.

Immunosuppressant Drug Index

Find the Immunosuppressive Compound Behind the Study

Immunosuppressant studies split by mechanism: CYP3A4 strong inhibitor requiring inhibitor-compensated DDI controls, CYP3A4 pure substrate requiring standard NADPH incubation, or UGT Phase II requiring UDPGA. Use the index to classify the mechanism before method development. The drug panel is intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags.

5 entries · Page 1 of 3

Analytical Pain Points

What Drives Assay Failure in Immunosuppressant Studies?

Immunosuppressant assays fail when CYP3A4 strong inhibitors are treated as pure substrates. CsA and tacrolimus suppress CYP3A4 probe activity to near-zero — a standard NADPH incubation measures their own inhibitory effect, not the test compound’s DDI liability. A single CYP3A4 method that fits sirolimus and everolimus produces unusable data for CsA and tacrolimus and zero data for mycophenolic acid.

CsA & Tacrolimus: CYP3A4 Strong Inhibitors

Cyclosporine A and tacrolimus are CYP3A4 strong inhibitors. In co-incubated DDI assays, they suppress CYP3A4 probe metabolism to near-zero — producing false-positive DDI data dominated by the immunosuppressant’s own inhibitory potency.

Our responseInhibitor-compensated sequential incubation: probe activity measured before and after CsA/tacrolimus inhibitor separation to isolate true test-compound DDI liability.

CYP Inhibition Assays →

Sirolimus & Everolimus: Pure Substrates

Sirolimus and everolimus are CYP3A4 substrates only — no inhibitor status. Their DDI risk is being inhibited by other drugs, not inhibiting others. Standard CYP3A4 incubation with NADPH covers both, if inhibitor controls are not needed.

Our responseStandard NADPH-supplemented CYP3A4 incubation for sirolimus and everolimus — pure-substrate kinetics without inhibitor compensation.

DDI Screening Services →

Mycophenolic Acid: UGT Phase II, Not CYP

Mycophenolic acid is metabolized by UGT1A9 and UGT2B7 via Phase II glucuronidation. CYP3A4 NADPH incubation adds nothing. Only UDPGA captures glucuronidation.

Our responseUDPGA-supplemented UGT1A9/UGT2B7 glucuronidation incubation — no NADPH, no CYP isoform panel, UGT-specific metabolite profiling.

Phase I & II Metabolite Characterization →

All Five: P-gp Transporters, One Analytical Dimension

Cyclosporine A, tacrolimus, sirolimus, and everolimus are all P-gp substrates. P-gp efflux interacts with CYP3A4 metabolism to determine systemic exposure. A CYP3A4-only method misses the P-gp disposition dimension.

Our responseP-gp substrate classification combined with CYP3A4 metabolism — dual readout for P-gp efflux and CYP3A4 clearance.

Transporter Interaction Bioanalysis →

Three Protocols in One Therapeutic Class

Inhibitor-compensated CYP3A4 (CsA, tacrolimus), standard CYP3A4 (sirolimus, everolimus), and UGT Phase II (mycophenolic acid) — three mutually exclusive incubation protocols within five compounds.

Our responseMechanism-matched multi-immunosuppressant panels: inhibitor-compensated arms, standard CYP3A4 arms, and UDPGA arms within one study.

Custom Panels →

Focused Service Paths

Four Practical Routes for Immunosuppressant Studies

Immunosuppressant workflows should be selected by mechanism: CYP3A4 strong-inhibitor DDI for CsA and tacrolimus; CYP3A4 pure-substrate metabolism for sirolimus and everolimus; UGT Phase II glucuronidation for mycophenolic acid; or mechanism-matched panels for mixed studies.

CYP3A4 Strong-Inhibitor DDI Profiling

For cyclosporine A and tacrolimus — inhibitor-compensated sequential incubation to isolate true test-compound DDI liability from CsA/tacrolimus inhibitory effects.

IC₅₀ CYP3A4 inhibition determination
Sequential probe-inhibitor separation protocol
P-gp substrate status parallel assessment

CYP Inhibition Assays →

CYP3A4 Pure-Substrate Metabolism

For sirolimus and everolimus — standard NADPH-supplemented CYP3A4 Phase I metabolism without inhibitor compensation.

Standard CYP3A4 incubation
Phase I metabolite profiling
P-gp disposition parallel analysis

Metabolite Identification →

UGT Phase II Glucuronidation

For mycophenolic acid — UGT1A9/UGT2B7 Phase II glucuronidation with UDPGA cofactor.

UGT1A9/UGT2B7 UDPGA incubation
Glucuronide metabolite identification
No CYP cofactor addition

Phase I & II Metabolite Characterization →

Custom Mechanism-Matched Immunosuppressant Panel

For mixed-mechanism studies: inhibitor-compensated CYP3A4, standard CYP3A4, and UDPGA arms within one validated panel.

Inhibitor-compensated arm (CsA, tacrolimus)
Standard CYP3A4 arm (sirolimus, everolimus)
UGT Phase II arm (mycophenolic acid)

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Immunosuppressant?

If your immunosuppressant is a CYP3A4 strong inhibitor, a pure CYP3A4 substrate, a UGT Phase II substrate, or a multi-mechanism combination — Creative Proteomics builds mechanism-matched workflows before method development.

Creative Proteomics classifies each compound as CYP3A4 strong inhibitor, CYP3A4 pure substrate, or UGT Phase II substrate — then selects cofactor, incubation protocol, and DDI control strategy accordingly.

Target immunosuppressant

Strong inhibitor / pure substrate / UGT

CYP3A4 inhibition IC₅₀

P-gp transport status

UGT cofactor requirement

Panel requirements